BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:12 PM
 | 
Nov 18, 2009
 |  BC Extra  |  Company News

FDA posts Aridol briefing documents

FDA posted briefing documents ahead of Friday's Pulmonary-Allergy Drugs Advisory Committee meeting to discuss an NDA from Pharmaxis Ltd. (ASX:PXS) for Aridol mannitol powder inhalation test to assess bronchial hyperresponsiveness (BHR) to aid in the diagnosis of patients ages six and up with symptoms of or suggestive of asthma. The panel will be asked whether the data...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >